Evidence map›Paper›PMID 32111756›Full record

ArticleIn vivo (Athens, Greece)

Successful Conversion Surgery Following Chylous Ascites After Nivolumab for Advanced Gastric Cancer.

Satoshi Toyota, Hiroyuki Orita, Yasuro Fukuyama, Saki Motoyoshi, Shogo Kawanami, Shohei Maeda, Erina Kuramitsu, Michihiro Ichimanda, Satoko Nagamatsu, Shigeyuki Nagata and 3 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Satoshi ToyotaDepartment of Surgery, Nakatsu Municipal Hospital, Nakatsu, Japan sa-toyoda@nakatsu-hosp.jp.
Hiroyuki OritaDepartment of Surgery, Nakatsu Municipal Hospital, Nakatsu, Japan.
Yasuro FukuyamaDepartment of Surgery, Nakatsu Municipal Hospital, Nakatsu, Japan.
Saki MotoyoshiDepartment of Surgery, Nakatsu Municipal Hospital, Nakatsu, Japan.
Shogo KawanamiDepartment of Surgery, Nakatsu Municipal Hospital, Nakatsu, Japan.
Shohei MaedaDepartment of Surgery, Nakatsu Municipal Hospital, Nakatsu, Japan.
Erina KuramitsuDepartment of Surgery, Nakatsu Municipal Hospital, Nakatsu, Japan.
Michihiro IchimandaDepartment of Surgery, Nakatsu Municipal Hospital, Nakatsu, Japan.
Satoko NagamatsuDepartment of Surgery, Nakatsu Municipal Hospital, Nakatsu, Japan.
Shigeyuki NagataDepartment of Surgery, Nakatsu Municipal Hospital, Nakatsu, Japan.
Seiichiro KaiDepartment of Surgery, Nakatsu Municipal Hospital, Nakatsu, Japan.
Daisuke KorenagaDepartment of Surgery, Nakatsu Municipal Hospital, Nakatsu, Japan.
Masaki MoriDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Saiseikai Nakatsu Hospital · JPKyushu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

case reportA 75-year-old man who underwent nivolumab as the third-line chemotherapy for advanced gastric cancer had chylous ascites (CA) after the primary tumor shrank remarkably. Total parenteral nutrition and subcutaneous octreotide were initiated, and CA disappeared. Nivolumab was continued for a total of 23 courses. Computed tomography showed lymph node swelling; however, staging laparoscopy showed that peritoneal metastasis had disappeared. Therefore, conversion surgery and distal gastrectomy with D1+ dissection were performed.

resultsThe pathological diagnosis was type IV, poorly differentiated adenocarcinoma (por2) with signet ring cells, ypT2 (muscularis propria), without lymphatic or venous invasion, and no involvement of the proximal and distal margins. After the operation, no recurrence was observed over 7 months with no adjuvant chemotherapy.

conclusionNivolumab has the potential to lead to R0 resection for patients with peritoneal carcinomatosis gastric cancer. To our knowledge, this is the first report of successful conversion surgery after nivolumab-related chylous ascites.

Indexed as

GastrectomyAgedAntineoplastic Agents, ImmunologicalChylous AscitesCombined Modality TherapyGastroscopyHumansLymphatic MetastasisMaleMolecular Targeted TherapyNeoplasm StagingNivolumabRadiography, AbdominalStomach NeoplasmsTomography, X-Ray ComputedTreatment OutcomeAntineoplastic Agents, ImmunologicalNivolumabchylous ascitesconversion surgeryGastric cancernivolumabperitoneal metastasispseudo progression

Identifiers

PMID32111756
PMCPMC7157868
OpenAlexW3007124284

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.